Compare AAT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | IVA |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | France |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2010 | N/A |
| Metric | AAT | IVA |
|---|---|---|
| Price | $19.48 | $6.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $20.00 | $16.20 |
| AVG Volume (30 Days) | ★ 491.6K | 463.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.69 | $2.70 |
| 52 Week High | $22.79 | $7.98 |
| Indicator | AAT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 60.76 |
| Support Level | $17.80 | $5.95 |
| Resistance Level | $19.32 | $6.72 |
| Average True Range (ATR) | 0.45 | 0.28 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 85.50 | 86.14 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.